Observational study on Mpox infection and its effects
Mpox Prospective Observational Cohort Study
Unity Health Toronto · NCT06291259
This study looks at how Mpox infection affects people's health, social lives, and mental well-being after the 2022 outbreak in Canada, by gathering information from participants during and after their illness.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Sex | All |
| Sponsor | Unity Health Toronto (other) |
| Locations | 3 sites (Vancouver, British Columbia and 2 other locations) |
| Trial ID | NCT06291259 on ClinicalTrials.gov |
What this trial studies
This multicentre prospective observational cohort study aims to investigate the clinical manifestations, social and psychological impacts, transmissibility, and viral shedding of Mpox infection following the 2022 outbreak in Canada. Participants will be enrolled during the acute phase of illness and will provide clinical data through chart reviews and interviews. The study is divided into two parts, with Part 1 focusing on the acute phase and Part 2 on the convalescent phase, which is optional. Data will be collected weekly until one week after the resolution of all symptoms.
Who should consider this trial
Good fit: Ideal candidates include individuals being investigated for Mpox infection based on clinical symptoms or exposure to confirmed cases.
Not a fit: Patients who have not been clinically confirmed to have Mpox infection or are outside the specified time frame for convalescence may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of Mpox infection, leading to improved management and treatment strategies for affected patients.
How similar studies have performed: While there have been few studies on Mpox, the unique focus on the recent outbreak and its effects makes this approach novel and potentially groundbreaking.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria Part 1: • Being investigated for Mpox infection by a clinician based on clinical (i.e. symptoms) and/or epidemiologic (i.e. exposure to confirmed case) grounds; Part 2: * Clinically confirmed to be in the convalescent phase (i.e. confirmed for Mpox infection previously) * Within 12 weeks of symptom onset Exclusion Criteria • None
Where this trial is running
Vancouver, British Columbia and 2 other locations
- BC Centre For Excellence — Vancouver, British Columbia, Canada (RECRUITING)
- Unity Health Toronto — Toronto, Ontario, Canada (RECRUITING)
- University Health Network — Toronto, Ontario, Canada (RECRUITING)
Study contacts
- Principal investigator: Darrell HS Tan, MD — Unity Health Toronto
- Study coordinator: Abby Li
- Email: abby.li@unityhealth.to
- Phone: 416-360-4000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.